Safe fertility-preserving management in a young woman with endometrial cancer

Endometrial cancer (EC) is a malignant cancer originating from the uterine endometrium. Although the incidence of endometrial cancer in reproductive age is relatively low, its impact on pregnancy outcome is critical. To date, it is difficult to find a standard method which can be referred to these patients who have a strong desire to preserve fertility. Presented is a report of a 35-year-old women with early-stage Endometrial cancer treated with progestin and levonorgestrel-releasing intrauterine system (LNG-IUS) with a good prognosis.

Endometrial cancer; Fertility-preserving; Progestin; Levonorgestrel-releasing intrauterine system

[1] Biler A., Solmaz U., Erkilinc S., Gokcu M., Bagci M., Temel O., et al.: “Analysis of endometrial carcinoma in young woman at a high-volume cancer center”. Int. J. Surg., 2017, 44, 185.

[2] Kalogera E., Dowdy S.C., Bakkum-Gamez J.N.: “Preserving fertility in young patients with endometrial cancer: current perspectives”. Int. J. Womens Health, 2014, 6, 691.

[3] Duska L.R., Garrett A., Rueda B.R., Haas J., Chang Y., Fuller A.F.: “Endometrial cancer in women 40 years old or younger”. Gynecol. Oncol., 2001, 83, 388.

[4] Kim S.W., Kim H., Ku S.Y., Suh C.S., Kim S.H., Choi Y.M.: “A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer”. Gynecol. Endocrinol., 2017, 34, 1.

[5] Tomao F., Peccatori F., Del Pup L., Franchi D., Zanagnolo V., Panici P.B., et al.: “Special issues in fertility preservation for gynecologic malignancies”. Crit. Rev. Oncol. Hematol., 2016, 97, 206.

[6] Bradford L.S., Rauh-Hain J.A., Schorge J., Birrer M.J., Dizon D.S.: “Advances in the management of recurrent endometrial carcinoma”. Am. J. Clin. Oncol., 2015, 8, 206.

[7] Gallos I.D., Yap J., Rajkhowa M., Luesley D.M., Coomarasamy A., Gupta J.K.: “Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis”. Am. J. Obstet. Gynecol., 2012, 207, 1.

[8] Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim K.R., Kim Y.T., et al.: “Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG. 2002)”. Eur. J. Cancer, 2013, 49, 868.

[9] Saegusa M., Okayasu I.: “Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis”. Cancer, 1998, 83, 111.

[10] Mentrikoski M.J., Shah A.A., Hanley K.Z., Atkins K.A.: “Assessing endometrial hyperplasia and carcinoma treated with progestin therapy”. Am. J. Clin. Pathol., 2012, 138, 524.

[11] Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E.: “Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review”. Gynecol. Oncol., 2012, 125, 477.

[12] Ushijima K., Yahata H., Yoshikawa H., Konishi I., Yasugi T., Saito T., et al.: “Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women”. J. Clin. Oncol., 2007, 25, 2798.

[13] Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E.: “Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review”. Gynecol. Oncol., 2012, 125, 477.

[14] Park J.Y., Nam J.H.: “Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer”. Oncologist, 2015, 20, 270.

[15] Qin Y., Yu Z.,Yang J., Cao D., Yu M., Wang Y., Shen K.: “Oral Progestin Treatment for Early-Stage Endometrial Cancer:A Systematic Review and Meta-analysis”. Int. J. Gynecol. Cancer, 2016, 26, 1081.

[16] Kalogera E., Dowdy S.C., Bakkum-Gamez J.N.: “Preserving fertility in young patients withendometrial cancer: current perspectives”. Int. J. Womens Health, 2014, 29, 691.

[17] Mi-La Kim, Seok Ju Seong.: “Clinical applications of Levonorgestrel-releasing intrauterine system to gynecologic diseases”. Obstet. Gynecol. Sci., 2013, 56, 67.

[18] Heikinheimo O., Gemzell-Danielsson K.: “Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS)”. Acta Obstet. Gynecol. Scand., 2012, 91, 3.

[19] Zhou H., Cao D., Yang J., Shen K., Lang J.: “Gonadotropin- Releasing Hormone Agonist Combined with a Levonogestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrialcarcinoma and complex atypical hyperplasia in young women”. Int. J. Gynecol. Cancer, 2017, 27, 1178.

[20] Karimi-Zarchi M., Mousavi A.S., Behtash N., Chiti Z., Bokaie M.: “Conservative management of young women with endometrial carcinoma or complex atypicalhyperplasia: report of three cases and literature review”. Eur. J. Gynaecol. Oncol., 2011, 32, 695

[21] Kim S.W., Kim H., Ku S., Suh C.S., Kim S.H., Choi Y.M.: “A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer”. Gynecol. Endocrinol., 2018, 34, 15.

[22] Falcone F., Laurelli G., Losito S., Di Napoli M., Granata V., Greggi S.: “Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer”. J. Gynecol. Oncol.,2017, 28, 2

[23] De Marzi P., Bergamini A., Luchini S., Petrone M., Taccagni G.L., Mangili G., et al.: “Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy”. J. Minim. Invasive Gynecol., 2015, 22, 1178.

[24] Gotlieb W.H., Beiner M.E., Shalmon B., Korach Y., Segal Y., Zmira N., et al.: “Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer”. Obstet. Gynecol., 2003, 102, 718.

[25] Park JY., Nam J.H.: “Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer”. Oncologist, 2015, 20, 270.

[26] Kalogera E., Dowdy S.C., Bakkum-Gamez J.N.: “Preserving fertility in young patients with endometrial cancer:current perspectives”. Int. J. Womens Health, 2014, 6, 691.

[27] Gamadauro P., Gudmundsson J.: “Endometrial cancer in a woman undergoing hysteroscopy for recurrent IVF failure”. Gyncecol. Surg., 2017, 14, 4. Nougaret S., Lakhman Y., Vargas HA., Colombo PE., Fujii S., Rein hold C. Sala E.: “From Staging to Prognostication Achievement and challenges of MR Imaging in the Assessment of endometrial cancer”. Magn. Reson. Imaging Clin N. Am.,2017, 25, 611.

[28] Morice P., Leary A., Creutzberg C., Abu-Rustum N., Darai E.: “Endometrial cancer”. Lancet, 2016, 387, 1094.